Last reviewed · How we verify

Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Sickle Cell Disease — Treatment Landscape & Competitive Intelligence

Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Sickle Cell Disease (disease) competitive landscape: 0 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

0 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Sickle Cell Disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

No marketed treatments tracked for this disease yet.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Sickle Cell Disease:

Cite this brief

Drug Landscape (2026). Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Sickle Cell Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bone-marrow-derived-mesenchymal-stem-cells-for-the-treatment-of-sickle-cell-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing